Compare Amphastar Pharmaceuticals Inc (AMPH) vs IQIYI Inc - ADR (IQ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

IQ trades at $1.13, down 0.88% on the day, with technical indicators neutral and mixed earnings history. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, though valuation ratios like P/S of 0.28 and P/B of 0.57 suggest potential undervaluation. Recent news highlights AI initiatives and leadership changes, while cash flow trends show volatility with a net inflow of $787.41M in 2025.

The outlook is cautious; analyst consensus is split with 50% buy ratings but profitability concerns persist. Risks include revenue declines, competitive pressures in streaming, and debt levels. Upside potential exists if AI-driven content strategies revive growth, but near-term volatility is likely amid earnings uncertainty.